Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Zidavi is recommended by the Infectious Disease Society of America
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
Krsnaa Diagnostics Limited has operationalized one diagnostics center at district hospital Male Akbarpur, Kanpur Dehat, Uttar Pradesh.
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Medical Tourism will boost India’s economy
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Subscribe To Our Newsletter & Stay Updated